•Orthocell granted US patent for its Celgro™ soft tissue reconstruction technology
• Patent relates to manufacture of novel bio-scaffolds to aid in the surgical repair of soft tissue injuries such as tendon, cartilage, bone and tissue, as well as the delivery of stem cells to relevant surgical sites
• Orthocell has patents previously granted in Singapore, China and New Zealand
Perth, Australia; 29 January 2015: Regenerative medicine company Orthocell Limited has today announced it has been granted a US patent for its Celgro™ soft tissue reconstruction technology.
The patent, entitled “A Collagen Scaffold for Cell Growth and a method producing the Same”, provides an important protection to the Celgro™ product in the US as Orthocell prepares for registrations and commercialisation in that market.
“This patent further strengthens our international IP position for our soft tissue reconstruction technology and comes at a perfect time for the company as we move our products through international registration processes as well as commercial partnerships such as our recent BoneSupport agreement,” Orthocell Managing Director Paul Anderson said.
Orthocell plans to file the first registration for approval of CelgroTM in the third quarter of calendar 2015 and is expanding production capacity to support sales.
Celgro™ is a novel bio-scaffold that overcomes or alleviates some of the problems associated with currently marketed bio-scaffolds. Many of these bio-scaffolds are not cell friendly, are prone to create immune reactions due to the presence of residual foreign cells from the host material, and a lack of sufficient mechanical properties required to withstand the harsh environments in which bio-scaffolds are regularly used in tendon, cartilage and tissue repair.
CelgroTM was developed to address many of the problems with existing bio-scaffolds with the result that Celgro™ boasts superior tissue in-growth and repair qualities, while exhibiting strong mechanical properties which can be tuned to accommodate the needs of the specific tissue repair. CelgroTM is also free of cells and DNA and is manufactured in a strict quality controlled cleanroom from Australian sourced raw materials that eliminates disease transmission concerns. Unlike many synthetic tissue repair devices approved globally, Celgro™ is highly compatible with human tissue and does not elicit an inflammatory response, as it is slowly resorbed into patient-generated healthy tissue.
Orthocell is excited about the potential for Celgro™ and believes that it offers significant commercial potential in its existing addressable orthopaedic market as well as much wider application in general surgical reconstructive applications, such as hernia and vaginal wall soft tissue repair, for which there are currently no approved synthetic scaffolds.
For more information, please contact:
General enquiries
Paul Anderson
Orthocell Limited, Managing Director
P: (08) 9360 2888
E: paulanderson@orthocell.com.au
Media enquiries
Gavin Lower
Buchan Consulting
P: (03) 8866 1215 / 0414 796 726
E: glower@buchanwe.com.au
Investor Relations
Rebecca Wilson
Buchan Consulting
P: 0417 382 391
E: rwilson@buchanwe.com.au
About Orthocell Limited
Orthocell is a commercial-stage, regenerative medicine company focused on developing products for a variety of tendon, cartilage and soft tissue injuries. Orthocell’s portfolio of products include TGA-approved stem cell therapies Autologous Tenocyte Implantation (Ortho-ATI™) and Autologous Chondrocyte Implantation (Ortho-ACI™), which aim to regenerate damaged tendon and cartilage tissue. The Company’s other major product is Celgro™, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approvals.
Help employers find you! Check out all the jobs and post your resume.
